BH3 MIMETICS

/ SCIENCE / By
  1. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
  2. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
  3. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer
  4. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
  5. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells
  6. Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
  7. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
  8. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t (11; 14) multiple myeloma
  9. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
  10. A BH3 mimetic for killing cancer cells
  11. ABT-199, a new Bcl-2–specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
  12. Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program
  13. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
  14. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2–Beclin1 interaction at endoplasmic reticulum
  15. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells
  16. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells
  17. In vitro effects of the BH3 mimetic,(−)-gossypol, on head and neck squamous cell carcinoma cells
  18. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
  19. A novel BH3 mimetic reveals a mitogen-activated protein kinase–dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species
  20. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia
  21. Reversal of cisplatin resistance with a BH3 mimetic,(−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL
  22. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
  23. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts
  24. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737
  25. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
  26. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis
  27. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B …
  28. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic …
  29. A novel BH3 mimetic S1 potently induces Bax/Bak‐dependent apoptosis by targeting both Bcl‐2 and Mcl‐1
  30. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
  31. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies
  32. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737
  33. Structural Basis of Bcl‐xL Recognition by a BH3‐mimetic α/β‐Peptide Generated by Sequence‐Based Design
  34. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells
  35. The BH3 mimetic ABT-737 induces cancer cell senescence
  36. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies
  37. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells
  38. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax
  39. Endogenous Noxa determines the strong proapoptotic synergism of the BH3-mimetic ABT-737 with chemotherapeutic agents in human melanoma cells
  40. BH3-mimetic drugs: blazing the trail for new cancer medicines
  41. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells
  42. The BH3 mimetic S1 induces autophagy through ER stress and disruption of Bcl-2/Beclin 1 interaction in human glioma U251 cells
  43. … is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (−)-Gossypol (AT-101)
  44. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice
  45. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
  46. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT …
  47. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts
  48. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study
  49. ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress
  50. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance
  51. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells
  52. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
  53. Interference with the HSF1/HSP70/BAG3 pathway primes glioma cells to matrix detachment and BH3 mimetic–induced apoptosis
  54. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells
  55. Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor–related apoptosis …
  56. Sorafenib sensitizes glioma cells to the BH3 mimetic ABT-737 by targeting MCL1 in a STAT3-dependent manner
  57. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy
  58. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the …
  59. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53
  60. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
  61. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression
  62. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis
  63. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
  64. The BH3 mimetic obatoclax accumulates in lysosomes and causes their alkalinization
  65. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics
  66. DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis
  67. Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1, 4, 5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263
  68. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
  69. Bcl-xL–inhibitory BH3 mimetic ABT-737 depletes platelet calcium stores
  70. … -induced apoptosis in non-small-cell lung cancer cells is dependent on Bax-and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 …
  71. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis
  72. The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca2+ signaling
  73. S63845, an MCL-1 selective BH3 mimetic: another arrow in our quiver
  74. The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
  75. BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737
  76. SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells
  77. HA14-1, but not the BH3 mimetic ABT-737, causes Ca2+ dysregulation in platelets and human cell lines
  78. Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells
  79. S1, a novel pan- BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak
  80. The BH3 mimetic S1 induces endoplasmic reticulum stress-associated apoptosis in cisplatin-resistant human ovarian cancer cells although it activates …
  81. Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis
  82. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells
  83. The BH3‐mimetic ABT‐737 inhibits allogeneic immune responses
  84. The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling
  85. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737
  86. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling
  87. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
  88. Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects
  89. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip1
  90. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
  91. Inhibition of JNK3 promotes apoptosis induced by BH3 mimetic S1 in chemoresistant human ovarian cancer cells
  92. A novel bioavailable BH3 mimetic efficiently inhibits colon cancer via cascade effects of mitochondria
  93. Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice
  94. The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
  95. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma
  96. Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells
  97. BH3‐domain mimetic compound BH3I‐2′ induces rapid damage to the inner mitochondrial membrane prior to the cytochrome c release from mitochondria
  98. Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in …
  99. Defective autophagy in multidrug resistant cells may lead to growth inhibition by BH3‐mimetic gossypol
  100. BH3-mimetic ABT-737 induces strong mitochondrial membrane depolarization in platelets but only weakly stimulates apoptotic morphological changes, platelet …
  101. Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells
  102. Identification of predictive factors of response to the BH3‐mimetic molecule ABT‐737: An ex vivo experiment in human serous ovarian carcinoma
  103. BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in …
  104. Gamma-tocotrienol acts as a BH3 mimetic to induce apoptosis in neuroblastoma SH-SY5Y cells
  105. Pancreatic cancer combination therapy using a BH3 mimetic and a synthetic tetracycline
  106. … -of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic …
  107. The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil
  108. The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid
  109. Canonical Bcl-2 motifs of the Na+/K+ pump revealed by the BH3 mimetic chelerythrine: early signal transducers of apoptosis?
  110. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
  111. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL
  112. Pharmacological blockade of Bcl-2, Bcl-x L and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice
  113. The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells
  114. The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells
  115. Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
  116. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid …
  117. Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2
  118. Metastatic SW620 colon cancer cells are primed for death when detached and can be sensitized to anoikis by the BH3-mimetic ABT-737
  119. Cytoprotective role of autophagy against BH3 mimetic gossypol in ATG5 knockout cells generated by CRISPR-Cas9 endonuclease
  120. BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma
  121. BAX-BAK1-independent LC3B lipidation by BH3 mimetics is unrelated to BH3 mimetic activity and has only minimal effects on autophagic flux
  122. MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA
  123. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed/refractory chronic lymphocytic leukemia: interim results of …
  124. 2-Deoxyglucose treatment complements the cisplatin-or BH3-only mimetic-induced suppression of neuroblastoma cell growth
  125. BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition
  126. Possible Mechanisms Of Resistance To The Novel BH3-mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk
  127. Preliminary results of a phase II open-label, randomized study of the BH3 mimetic protein navitoclax (ABT-263) with or without rituximab for treatment of …
  128. Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic
  129. BH3 mimetic-elicited Ca 2+ signals in pancreatic acinar cells are dependent on Bax and can be reduced by Ca 2+-like peptides
  130. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer
  131. BCL-2-Selective BH3 mimetic ABT-199 Is a potent agent for acute myeloid leukemia
  132. Effect of the BH3 mimetic Polyphenol (–)-Gossypol (AT-101) on the in vitro and in vivo Growth of Malignant Mesothelioma
  133. BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis
  134. Pan‐ BH3 mimetic S1 Exhibits Broad‐Spectrum Antitumour Effects by Cooperation between Bax and Bak
  135. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma
  136. Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737
  137. ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca2+‐signalling dysregulation or toxicity in pancreatic acinar cells
  138. Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies
  139. The BH3-mimetic Obatoclax Restores the Response to Dexamethasone in Glucocorticoid-Resistant ALL through Induction of Autophagy.
  140. A novel BH3 mimetic reveals a MAPK-dependent mechanism of melanoma cell survival controlled by p53 and reactive oxygen species
  141. The pro-death role of autophagy and apoptosis in cell death induced by the BH3 mimetic gossypol
  142. A small molecule BH3-mimetic suppresses cigarette smoke-induced mucous expression in airway epithelial cells
  143. Computational analyses on delineating specificity of 2-hydroxy-3, 5-dinitrobenzamide, a BH3-mimetic, towards anti-apoptotic proteins
  144. Combination Treatment with the BRAFV600E Inhibitor Vemurafenib and the BH3 mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma
  145. BH3 mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo
  146. The PPARγ agonist rosiglitazone sensitizes the BH3 mimetic (−)‐gossypol to induce apoptosis in cancer cells with high level of Bcl‐2
  147. Pushing cancer cells to commit suicide: Is 072RB, the new BH3 mimetic, up to the job?
  148. BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia
  149. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
  150. The BH3-mimetic obatoclax (GX15-070) posses a dual-mechanism of action and induces both apoptosis and autophagy-dependent cell death of B cell non-Hodgkin’s …
  151. Combination therapy with BH3 mimetic and hyperthermia tends to be more effective on anti-melanoma treatment
  152. Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737
  153. Effect of the BH3 mimetic ABT-737 on human melanoma cells to apoptosis induced by selective BRAF inhibitors.
  154. Nutrient starvation sensitizes human ovarian Cancer SKOV3 cells to BH3 mimetic via modulation of mitochondrial dynamics
  155. Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).
  156. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
  157. Cell Death Induction by the Indirubin Derivative 7BIO and the BH3 mimetic Drugs ABT-737 and GX15-070 in Medullary Thyroid Carcinoma Cells
  158. Obatoclax, a BH3 mimetic, enhances cisplatin-induced apoptosis and decreases the clonogenicity of muscle invasive bladder cancer cells via mechanisms that involve …
  159. Autophagy-mediated growth inhibition of malignant glioma cells by the BH3-mimetic gossypol
  160. A Dual BH3-mimetic approach targeting BCL-2 and MCL1 is highly efficacious and well-tolerated in Acute Myeloid Leukemia
  161. MIM1, the Mcl-1–specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells
  162. Targeting the apoptotic machinery of pediatric acute lymphoblastic leukemia in vivo using the BH3-mimetic ABT-737
  163. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and …
  164. BH3 mimetic Augments the Induction of Apoptosis by INNO-406, a Novel Bcr-Abl/Lyn Inhibitor, in Bcr-Abl+ Leukemic Cells.
  165. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors
  166. Targeting the BCL-2 family of proteins in hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the BH3 mimetic ABT-737
  167. BCL-2 Phosphorylation Modulates Sensitivity to the BH3-mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic …
  168. Disruption of Bcl-2 Heterodimerization by the BH3 mimetic ABT-737 Restores Spontaneous Apoptosis and Induces Differentiation in High Risk MDS and AML.
  169. By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737
  170. Intrinsic resistance of prostate cancer to the BH3 mimetic ABT-737 is related to expression of the anti-apoptotic Mcl-1 and additional survival and apoptosis regulating …
  171. Studies of the combination of ABT-199, a BH3 mimetic that specifically targets Bcl-2 in combination with chemotherapy and the proteosome inhibitor bortezomib in” …
  172. … 2 Dual Inhibitors Created by the Structure‐Based Hybridization of Drug‐Divided Building Blocks and a Fragment Deconstructed from a Known Two‐Face BH3 Mimetic
  173. Bim–BH3-mimetic tHerapy for ra
  174. RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines
  175. BRAF inhibition is enhanced by BH3-mimetic through BIM induction.
  176. Decoding The BH3-mimetic Pro-Apoptotic Activity Of Quercetin In Jurkat Cells
  177. Novel BH3 mimetic based therapeutic strategies for the treatment of breast cancer
  178. inhibitory BH3 mimetic ABT-737 depletes platelet calcium stores− L Bcl-x
  179. … FOR THE USE OF MCL1/BCL2 BH3 mimetic COMBINATION TO EFFECTIVELY KILL PRIMARY MYELOMA CELLS INSENSITIVE TO EACH BH3 mimetic ALONE …
  180. Apoptosis mechanism induced by BH3 mimetic S1 in human leukemia cell line K562
  181. Efficacy of the BH3-mimetic ABT-199 in acute lymphoblastic leukemia
  182. To explore the use of a BH3-mimetic (ABT-737) as a chemosensitizer of osteosarcoma cells to doxorubicin.
  183. Activity of the BH3 mimetic ABT-737 on Polycythemia Vera (PV) Erythroid Precursor Cells
  184. Design and activity detection of BH3-mimetic peptide based on Bcl-XL binding potency
  185. The BH3 mimetic navitoclax (ABT-263) selectively induces apoptosis in cholangiocarcinoma-associated fibroblasts thereby reducing tumor growth
  186. Identification of Potent BH3-mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia
  187. A p21Cip1-dependent autophagic cell death by BH3-mimetic gossypol in mutant BRAF melanoma cells (796.4)
  188. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly
  189. Maritoclax, a selective Mcl-1 inhibitor, sensitizes melanoma cells to the Bad BH3-mimetic ABT-737.
  190. IDENTIFICATION OF POTENT BH3-mimetic COMBINATIONS TARGETING PRO-SURVIVAL PATHWAYS IN HUMAN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
  191. Relationship between BH3 mimetic S1 and expression of BCL-2 family members in acute myeloid leukemia
  192. Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.
  193. DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis
  194. The BH3 mimetic GX015-070 (Obatoclax) induces apoptosis and growth inhibition in neoplastic mast cells
  195. Induction of Bim by the BRAF inhibitor PLX4720 sensitizes human melanoma cells to the BH3 mimetic ABT-737
  196. Abstract P2-09-01: Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer
  197. BH3-mimetic gossypol promotes autophagy to inhibit the proliferation of mutant BRAF melanoma cells with high expression of p21Cip1
  198. Inhibition of prosurvival autophagy by the BH3-mimetic obatoclax sensitizes antiestrogen-resistant breast cancer cells to apoptosis
  199. Failure of autophagy induction makes multidrug resistant cells vulnerable to BH3-mimetic gossypol
  200. Abstract A28: Apoptosis induction with the MEK inhibitor AZD6244 and BH3 mimetic ABT-737 in melanoma.
  201. PL-09. MEDULLOBLASTOMA IS PRIMED FOR RAPID APOPTOSIS BY CONSTITUTIVELY ACTIVE BAX AND IS HIGHLY SENSITIVE TO BH3 mimetic THERAPY
  202. Functional disparity among BCL-2 members in tonsillar and leukemic B cell subsets probed by next generation BH3 mimetic profiling
  203. 695 The BH3 Mimetic, Small Molecule, ABT-737, Was Effective As Lympholytic Therapy in the MRL/lpr-/-Mouse Model of Autoimmune Lymphoproliferative Syndrome …
  204. S1, a Bid-like BH3 mimetic, induces apoptosis by dynamic change of Mcl-1 and dependent on Bak, not Bax
  205. Acquired cisplatin resistance in malignant pleural mesothelioma cells is reversed by both BH3-mimetic obatoclax and IAP-inhibitor AT-406
  206. Broad spectrum BH3 mimetic BI-97D6 induces apoptosis of acute myeloid leukemia cells even when co-cultured with supporting stromal cells
  207. ABT-737, A BH3 MIMETIC, LEADS TO RADIOSENSITIZATION OF HEAD AND NECK SQUAMOUS CELL CARCINOMA VIA INDUCTION OF INTRAMITOCHONDRIAL …
  208. The BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptosis by releasing Bim and Bak proteins in human pancreatic cancer cells
  209. Combination of the IGF-1 Receptor Inhibitor Picropodophylin and the BH3 mimetic ABT-737 Has Synergistic Anti-Myeloma Activity
  210. Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck
  211. A potent BH3 mimetic targeting BCL-XL induces apoptosis regulated by PTEN loss and integrin alpha 5 in prostate cancer cells
  212. The BH3 mimetic Obatoclax (GX015-070) synergistically enhances TRAIL-mediated apoptosis by activating Bak and Bax in human pancreatic cancer cells
  213. Identification of a novel mechanism by which the BH3 mimetic obatoclax sensitizes non-Hodgkin’s lymphoma tumor cells to TRAIL-mediated apoptosis
  214. The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein
  215. Combining the anti-mesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cell lines.
  216. The BH3 Mimetic, Small Molecule, ABT-737, Was Effective As Lympholytic Therapy in the MRL/lpr−/− Mouse Model of Autoimmune Lymphoproliferative Syndrome …
  217. The BH3-mimetic ABT-737 Reverses the Intrinsic Radioresistance of Head and Neck Squamous Carcinoma Stem and Non-stem Cells
  218. Abstract LB-23: In vivo exposure of infant leukemia to the BH3-mimetic ABT-263 selects for a cell death-resistant phenotype
  219. Microfluidic profiling of apoptosis-related genes after treatment with BH3-mimetic agents in astrocyte and glioblastoma cell lines
  220. Abstract B26: Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts
  221. Possible molecular mechanisms and pathways involved in BH3 mimetic activity of alpha-lipoic acid on human colon cancer cell line
  222. S110 (−)-Gossypol, a BH3 mimetic and Inducer of Apoptosis in Head and Neck Cancer Cells, Is Oxidized and Deactivated by ROS
  223. S63845, a novel BH3 mimetic Mcl-1 inhibitor synergizes with midostaurin to induce potent apoptosis in acute myeloid leukemia cells carrying FLT3-ITD mutations
  224. A short term biomarker-based assay predicts apoptotic response to combined BCL-2/MCL-1 BH3 mimetic targeting in Myeloma cells
  225. Supplemental data Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
  226. Abstract# 374: BH3 mimetic, ABT-737, enhances celecoxib-induced apoptosis that can be further augmented by inhibition of autophagy in human colon cancer cells.
  227. Abstract# 2786: Apoptosis induced by JAK2 inhibition requires Bim and is enhanced by a BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells
  228. BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
  229. Mechanisms underlying synergistic interactions between the CDK inhibitor flavopiridol (Alvocidib) and the BH3 mimetic GX15-070 (Obatoclax) in human multiple …
  230. The BH3-mimetic GX15-070 induces autophagy-dependent cell death of therapy-sensitive and-resistant aggressive B cell non-Hodgkin’s lymphoma (B-NHL)
  231. The BH3 mimetic compound BH3I-1 impairs mitochondrial dynamics and promotes stress response in addition to its pro-apoptotic key function
  232. P2. 05-004 ABT-737, a BH3 Mimetic, Enhances Therapeutic Effect of Ionizing Radiation in Murine Lung Cancer Model: Topic: Biology
  233. The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid …
  234. Synergistic cytotoxic/apoptotic effects of AT-101, a phytochemical with BH3-mimetic property, in combination with paclitaxel in human breast cancer cells.
  235. Cover Picture: Structural Basis of Bcl‐xL Recognition by a BH3‐mimetic α/β‐Peptide Generated by Sequence‐Based Design (ChemBioChem 13/2011)
  236. Examination of 4-hydroxy tamoxifen-and BH3 mimetic-induced cell death pathways in glioblastoma and malignant peripheral nerve sheath tumor cells
  237. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma
  238. Supplemental data The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
  239. Abstract# 3276: The BH3 mimetic Obatoclax (GX15-070) sensitized B-NHL cells to TRAIL-mediated apoptosis by activating Bak and inhibiting Mcl-1, NF-# 954; B and …
  240. Compounds and methods for inducing apoptosis in cancer cells using a BH3 alpha-helical mimetic

Related Posts

Shopping Cart
Scroll to Top